| 425 |
Why I Chose SAPIEN as No. 1 Valve |
Jung-Hee Lee |
Apr. 17. 25 |
| 424 |
The Right Time to Treat |
Philippe Genereux |
Apr. 17. 25 |
| 423 |
TAVR in the Elderly: Futility Versus Utility |
Tullio Palmerini |
Apr. 17. 25 |
| 422 |
Management of Annular Rupture During TAVR |
Kam Tim Chan |
Apr. 17. 25 |
| 421 |
How to Minimize Conduction Disturbance After TAVR? |
Yohei Ohno |
Apr. 17. 25 |
| 420 |
Valve-in-Valve TAVI in Stentless Bioprosthesis Surgical Valves |
Wojciech Wojakowski |
Apr. 17. 25 |
| 419 |
Initial Experience of a Novel Intra-Annular Self-Expanding Valve (Navitor) in Japan |
Kentaro Hayashida |
Apr. 17. 25 |
| 418 |
Case Presentation |
Kid Bhumimuang |
Apr. 17. 25 |
| 417 |
Gender-Specific Approach for TAVI in Female Patients |
Wacin Buddhari |
Apr. 17. 25 |
| 416 |
ENAVO-TAVR Trial: SGLT-2 Inhibitor for Post-TAVR Patients |
Soo Yeon An |
Apr. 17. 25 |
